As research into the mechanisms of action of SGLT2 inhibitors continues to evolve, these agents may offer a valuable strategy for mitigating cardiotoxicity in cancer patients, particularly those at high risk for developing cardiovascular complications during cancer therapy. Here, SLC5A2 is linked to cancer.